Farallon Capital Management LLC has recently announced that it has increased stake in Savara Inc. (NASDAQ:SVRA) by 16.49%. After grabbing 9.91 million shares, the institutional investor is now in possession of 1.4 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 8.69% having worth around $15.36 million. Moreover, AXA Investment Managers UK Ltd. increased its share by 14736.0 to have a control over 3.43 million shares. And Kayne Anderson Rudnick Investment raised its holdings to 1.22 million shares by acquiring 1.22 million shares or 1.07% of the stake.
Savara Inc. (SVRA) concluded trading on 01/18/23 at a closing price of $1.92, with 0.36 million shares of worth about $0.7 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 4.92% during that period and on Wednesday the price saw a gain of about 1.59%. Currently the company’s common shares owned by public are about 152.77M shares, out of which, 111.83M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 5 analysts are covering the SVRA stock and their offered price forecasts bring an average price target of $4.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $7.00 and could fall to a lowest price of $2.00. The stock’s current price level is 52.0% above of average price target set by the analysts, while a rise to estimated low would result in gain of 4.0% for the stock. However, touching the estimated high of $7.00 would mean a gain of 72.57% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 27 times over the past 12 months. They bought 1,041,454 shares in 27 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
AXA Framlington Biotech Fund, Vanguard Total Stock Market Index, and Vanguard Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Savara Inc. AXA Framlington Biotech Fund is currently holding 3.27 million shares of worth totaling $5.07 million. The company recently came buying 67612.0 shares which brought its stake up to 2.87% of the company’s outstanding shares. Vanguard Extended Market Index Fu, after buying 1.36 million shares, have now control over 1.20% of the stake in the company. It holds 0.0 shares of worth $2.11 million.
Savara Inc. (NASDAQ: SVRA) started trading at $1.90, above $0.01 from concluding price of the previous day. However, the stock later moved at a day high price of 1.9500, or with a gain of 1.59%. Stock saw a price change of 10.34% in past 5 days and over the past one month there was a price change of 21.52%. Year-to-date (YTD), SVRA shares are showing a performance of 23.87% which increased to 47.69% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.02 but also hit the highest price of $1.91 during that period. The average intraday trading volume for Savara Inc. shares is 109.16K. The stock is currently trading 17.40% above its 20-day simple moving average (SMA20), while that difference is up 27.93% for SMA50 and it goes to 32.46% higher than SMA200.
Farallon Capital Management LLC acquired 9.91 million shares of Savara Inc. having value of about $15.36 million. Data submitted at the U.S SEC by Farallon Capital Management LLC revealed that the firm now holds 1.4 million shares in the company valued at close to $2693151.36, or have control over 16.49% stake in the company. Savara Inc. (NASDAQ: SVRA) currently have 152.77M outstanding shares and institutions hold larger chunk of about 70.50% of that. Holding of mutual funds in the company is about 27.36% while other institutional holders and individual stake holders have control over 8.99% and 25.78% of the stake respectively.
The stock has a current market capitalization of $215.40M and its 3Y-monthly beta is at 0.76. It has posted earnings per share of -$0.27 in the same period. It has Quick Ratio of 26.50 while making debt-to-equity ratio of 0.22. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SVRA, volatility over the week remained 6.14% while standing at 6.67% over the month.
Analysts are in expectations that Savara Inc. (SVRA) stock would likely to be making an EPS of -$0.07 in the current quarter, while forecast for next quarter EPS is -$0.08 and it is -$0.29 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.07 which is -$0.06 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.07 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 61.60% while it is estimated to decrease by -12.00% in next year.
Analysts at 5 brokerage firms have issued recommendations for the Savara Inc. (SVRA)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.60. Out of those 5 Wall Street analysts, 5 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on March 16, 2021 offering an Overweight rating for the stock and assigned a target price of $7 to it. Coverage by Oppenheimer stated Savara Inc. (SVRA) stock as an Outperform in their note to investors on March 15, 2021, suggesting a price target of $4 for the stock. On June 13, 2019, H.C. Wainwright Reiterated their recommendations, while on June 13, 2019, Ladenburg Thalmann Downgrade their ratings for the stock with a price target of $3. Stock get a Mkt perform rating from JMP Securities on June 13, 2019.